Introduction
Chronic kidney disease (CKD), defined as glomerular filtration rate (GFR) <60 ml/ min/1.73 m 2 or abnormal levels of albumin uria, is a major public health problem affecting 8-12% of adults in industrial ized countries. 1, 2 GFR is inversely related to the risks of cardio vascular disease and allcause mortality. In a populationbased study, the risks of ageadjusted mortal ity for patients with CKD stages 3a (GFR 45-59 ml/min/1.73 m 2 ), 3b (GFR 30-44 ml/ min/1.73 m 2 ) and 4, were found to be 1.2, 1.8 and 3.2 times higher, respectively, than the risks for patients with GFR ≥60 ml/ min/1.73 m. 3 In the Valsartan in Acute Myocardial Infarction (VALIANT) study, each 10 ml/min/1.73 m 2 reduction in GFR below 81 ml/min/1.73 m 2 was found to increase the risk of allcause mortality by 10%. 4 Furthermore, a rapid annual decline in GFR (≥5.6%) is associated with 30% and 22% increased risks of coronary heart disease and allcause mortality, respectively. 5 Currently, established therapies for slowing the progression of CKD and pre venting cardiovascular events and death in the CKD population are limited. Bloodpressurelowering agents, such as angiotensinconvertingenzyme inhibi tors (ACEIs) and angiotensinreceptor blockers (ARBs), are effective at slowing kidney disease progression and have proven cardio vascular benefits. 6, 7 Lipid lowering agents have benefits in early CKD, but their efficacy in advanced kidney disease remains to be confirmed. Despite the progress that has been made in under standing the effects of these existing thera pies, people with CKD continue to have unacceptably high rates of cardiovascular morbidity and mortality. [8] [9] [10] These poor outcomes may be caused by the presence of other novel and potentially modifiable risk factors.
Is uric acid a risk factor?
Increasing data suggest that uric acid may be a risk factor or biomarker for both renal and cardiovascular outcomes in a range of populations.
General population
Several observational studies have demon strated associations between serum uric acid levels and various outcomes, including albuminuria, blood pressure, cardiovascular events, and mortality. Detailed discussion is beyond the scope of this Perspectives article, but it has been reviewed by other researchers. 11, 12 Prospective epidemiological studies have established that high uric acid levels are linked to the development of both newonset CKD and endstage renal disease (ESRD). A summary of studies that exam ined the relationship between uric acid level and various clinical outcomes is provided in Supplementary Table 1 online. In a study involving 3,499 apparently healthy adults, the risk of developing incident CKD (GFR <60 ml/min/1.73 m 2 ) was highest among participants in the highest quartile for serum uric acid concentration. 13 Similarly, in a large study of 177,570 healthy volun teers, it was observed that the risk of devel oping incident ESRD was more than twofold higher in participants with uric acid levels in the highest quartile than in individuals with uric acid levels in the lowest quartile.
14 Another survey from Japan, which involved 48,177 participants, reported a similar finding in women, but not in men. 15 In a communitybased investigation involv ing 21,475 participants in Austria, the risk of developing incident CKD was 26% higher in individuals with a serum uric acid level within the range 416-526 μmol/l (7-9 mg/dl), and 63% higher in indivi duals with a serum uric acid level >526 μmol/l (>9 mg/dl), compared with the risk in individuals with a serum uric acid level <416 μmol/l (<7 mg/dl). 16 Combined data from the Atherosclerosis Risk in Communities and Cardiovascular Health Studies (involving a total of 13,338 patients) showed that every 59 μmol/l (1 mg/dl) increase in baseline serum uric acid level was associated with a 7% increase in the risk of incident CKD. 17 This finding contrasted with that of a separate analysis of partici pants of the Cardiovascular Health Study, which found no association between serum uric acid level and incident CKD, although patients in the fourth and fifth highest quintiles of serum uric acid concentra tion were more likely to have experienced Abstract | Observational studies have shown that asymptomatic hyperuricemia is associated with increased risks of hypertension, chronic kidney disease (CKD), endstage renal disease, cardiovascular events, and mortality. Whether these factors represent cause, consequence or incidental associations, however, remains uncertain. Hyperuricemia could be a consequence of impaired kidney function, diuretic therapy or oxidative stress, such that elevated serum urate level represents a marker, rather than a cause, of CKD. On the other hand, small, short-term, single-center studies have shown improvements in blood-pressure control and slowing of CKD progression following serum urate lowering with allopurinol. An adequately powered randomized controlled trial is required to determine whether uric-acid-lowering therapy slows the progression of CKD. This article discusses the rationale for and the feasibility of such a trial. International collaboration is required to plan and conduct a large-scale multicenter trial in order to better inform clinical practice and public health policy about the optimal management of asymptomatic hyperuricemia in patients with CKD.
www.nature.com/nrneph a rapid decline in GFR (≥3 ml/min/1.73 m 2 per year). 18 Part of the apparent disparity in results with the combined study may be explained by the fact that the Cardio vascular Health Study only included elderly participants aged ≥65 years.
CKD population
Although hyperuricemia is a ubiquitous finding in patients suffering from CKD, 19, 20 the relationship between hyperuricemia and either GFR decline or cardio vascular disease is less well established in this group than in the general population; the avail able studies are small and report conflicting results. In a study of 177 nondiabetic CKD patients (mean baseline GFR 64 ± 39 ml/ min/1.73 m 2 ), patients who reached a renal end point (serum creatinine dou bling or ESRD requiring dialysis) were not found to have higher uric acid levels than indivi duals who didn't reach these end points (416 ± 95 μmol/l [7 ± 1.6 mg/dl] versus 394 ± 95 μmol/l [6.63 ± 1.6 mg/dl]; P = 0.14). 20 No association between uric acid and CKD progression was observed after adjustment for baseline GFR and protein uria. A similar finding was reported in a retrospective analy sis of 223 patients with IgA nephropathy, in which hyper uricemia was observed to be associated with an increased risk of progressive CKD. 21 This association was no longer statisti cally significant after adjustment for age, gender, BMI, proteinuria, hyper tension, diabetes, hypercholesterolemia, and hyper triglyceridemia. 21 Interestingly, a direct correlation is reported to exist between serum uric acid level and histo logical evi dence of chronic tubulointerstitial changes in patients with IgA nephropathy. 22 In patients who have ESRD managed with peritoneal dialysis, hyperuricemia is linked to a rapid decline in residual renal function and increased endothelial dysfunction. 23, 24 On the other hand, longterm followup of 838 patients in the Modification of Diet in Renal Disease (MDRD) study did not show any associa tion between increased uric acid level and progression of CKD, 25 although each 59 μmol/l (1 mg/dl) increase in serum uric acid concentration was associ ated with 17% and 16% increased risks for allcause and cardiovascular mortality, respectively. Conclusions made by other researchers have been inconsistent: high serum uric acid levels have been reported to be associ ated with increased, 26 decreased 27 and neutral 28 effects on mortality in patients with CKD.
Kidney transplantation
In kidney transplant recipients, reported associations between serum uric acid levels and renal and mortality outcomes have varied. In one prospective investigation of 90 prevalent renal transplant patients, a single standard deviation increase in serum uric acid level was associated with a 22% lower GFR after 2 years; however, baseline uric acid level was not predictive of change in GFR over time. 29 Similarly, a study published in 2010 showed that an elevation in serum uric acid of ≥59.48 µmol/l (≥1 mg/dl) was associated with a 26% increase in the risk of graft loss, but not with the risk of death. 30 Conversely, a retrospective analysis of 307 transplant recipients showed no relation ship between uric acid level and time to new cardiovascular event or biopsyproven chronic allograft nephropathy. 31 
Urate-lowering therapy in CKD
Cardiovascular outcomes A few small, shortterm, singlecenter studies have indicated that xanthine oxidase inhibitors may exert favorable effects on cardiovascular risk factors and surrogate outcome measures. Xanthine oxidase inhibi tion by allopurinol or oxypurinol has been shown to improve endothelial dysfunction in selected populations-such as patients with congestive heart failure 32 and smokers. 33 Moreover, Feig and colleagues 34 showed in a doubleblind, randomized controlled trial (RCT) that allopurinol (200 mg twice daily), but not placebo, signifi cantly reduced mean systolic blood pressure (-6.9 mmHg, 95% CI -4.5 mmHg to -9.3 mmHg; P = 0.009) and mean diastolic blood pressure (-5.1 mmHg, 95% CI -2.5 mmHg to -7.8 mmHg; P = 0.05) over 4 weeks in 30 adolescents (aged 11-17 years) with newly diagnosed hyper tension, no evidence of CKD and no prior exposure to antihypertensive medications (Table 1) . In a prospective, intervention trial, Shelmadine et al. 35 observed that treatment of 12 hemodialysis patients with allopurinol 300 mg twice daily for 3 months resulted in signifi cant reductions in levels of serum uric acid (-210 μmol/l [3.53 mg/dl]) and LDL cholesterol (-0.36 μmol/l [14 mg/dl]). The dose of allopurinol used in this study was higher than is recommended for patients with impaired kidney function; however, information on hemodynamic parameters and adverse events was not reported.
Renal outcomes
Shortterm studies suggest that lowering serum urate levels with allopurinol may have beneficial effects on renal function. In a retrospec tive study of 134 liver trans plant recipi ents, eight patients with gout and 10 patients with asymptomatic hyper uricemia received allopurinol. 36 Over a median followup period of 3 months, mean serum creatinine concentration decreased from 177 ± 15.6 μmol/l to 160 ± 13.2 μmol/l (P = 0.01). 36 Although these results are encouraging, they are limited by a small sample size, short followup dura tion, retrospec tive study design (which increases the possibility of recall bias) and lack of random ization (which increases the possibility of confounding by indication).
Siu and coworkers 37 studied the effect of the lowering of serum uric acid level on progression of CKD in an openlabel RCT of allopurinol therapy (100-200 mg daily) for 12 months in 54 patients (mean age 48 years; 25% with diabetes) with proteinuria >0.5 g per day and creatinine >120 μmol/l (Table 1) . At baseline, mean serum creatinine concen trations in the allopurinol and control group were 146 ± 56 μmol/l and 164 ± 61 μmol/l, respectively. After 12 months, mean serum creatinine increased to 255 ± 85 μmol/l in the control arm, but remained unchanged at 176 ± 81 μmol/l in the allopurinol arm (P = 0.08). Allopurinol had no effect on proteinuria. Overall, 12% of patients in the allopurinol arm experienced worsening of kidney function, compared with 42% in the control arm. Only one of 25 patients receiving allopurinol developed a druginduced skin rash that necessitated cessation of medica tion. This trial was also limited by inadequate power and its openlabel study design.
Goicoechea et al. randomized 113 patients with CKD (estimated GFR [eGFR] <60 ml/ min/1.73 m 2 ) to allopurinol 100 mg daily or no study medication. 38 After 24 months, eGFR decreased by 3.3 ± 1.2 ml/min/1.73 m 2 in the control group and increased by 1.3 ± 1.3 ml/min/1.73 m 2 in the allopurinol group (P = 0.018). No differences in blood pressure between groups were reported. 15 of 56 patients in the control arm and seven of 57 patients in the allopurinol arm experi enced a cardiovascular event (hazard ratio [HR] 0.29, 95% CI 0.09-0.86; P = 0.026). Allopurinol was withdrawn in two patients as a result of gastrointestinal symptoms. No hematologic or other serious adverse events were reported. Although these results are encouraging, this trial was limited by inad equate power, openlabel and singlecenter design. It is unclear if allocation concealment was adequate and whether the assessors were blinded.
Kao and colleagues studied the effects of allopurinol 300 mg daily on cardiovascular surrogate measures over 9 months in 53 patients with stage 3 CKD and left ventricu lar hypertrophy in a doubleblind, placebo controlled RCT. 39 Compared with placebo, treatment with allopurinol was associated with a reduction in left ventricular mass index (placebo 1.28 ± 4.45 g/m 2 versus allopurinol -1.42 ± 4.67 g/m 2 ; P = 0.036) and improvement in flowmediated dilatation of the brachial artery (placebo -1.05 ± 2.84% versus allopurinol 1.26 ± 3.06%; P = 0.036). No effect of allopurinol on pulse wave velo city was noted. The authors reported that allopurinol was well tolerated and renal function remained stable in both groups. Publication of this trial is awaited.
Proposed study design
Justification A growing body of evidence links high uric acid levels with the development of hyper tension, CKD, ESRD, cardiovascular events, and death; but most of these data originate from animal studies, clinical observational studies, posthoc analysis of RCTs, and a few small RCTs. No adequately powered RCTs have yet demonstrated the bene ficial effects of uricacidlowering therapy on renal and cardiovascular outcomes in CKD; however, hyperuricemia in CKD could be a consequence of reduced kidney func tion, treatment with diuretics, and oxidative stress. Whether hyperuricemia is a marker of disease, an indirect marker of kidney func tion, or whether it has a causative role, is not yet clear. An adequately powered, double blind, placebocontrolled RCT evaluating the effects of uratelowering therapy on renal and cardiovascular outcomes is needed, to estab lish causality and inform clinical practice and public health policy about the benefits and risks associated with treating asymptom atic hyper uricemia in patients with CKD. Although the challenges in under taking such a trial are considerable, we propose a potential study design in Figure 1 .
Choice of primary outcome measures
We suggest an initial 'proofofconcept' pilot RCT with surrogate outcome mea sures (change in uric acid level, change in GFR, change in proteinuria, change in systolic and diastolic blood pressures, and change in pulse wave velocity) before pro ceeding to a much larger study adequately powered for patientlevel outcomes (such as the composite outcome of halving GFR, ESRD requiring renal replacement therapy, or renal death, and/or a composite cardio vascular outcome). The advantages of a surrogate endpoint study include smaller sample size (a few hundred patients versus thousands for an outcome trial), shorter followup (24 months), and substantially lower trial costs. Such a pilot trial would also determine the power, feasibility and design for a subsequent outcome trial if it indicated likely beneficial effects. The added advantages of a surrogate outcome study are that it would generate important data on the safety of the interventional agent and the practic ability of patient recruit ment, thereby allowing better planning for a 'hard endpoint' study, although it will not directly inform clinical practice.
Although the principal fo cus of the proposed trial is on renal outcomes, the associa tion between uric acid and cardio vascular disease, coupled with the markedly increased burden of cardiovascular disease in CKD, strongly supports using cardio vascular events as important secondary outcome measures in a largescale study with hard end points.
Patient population
Most observational evidence pertaining to uric acid and CKD progression comes from ) and improved brachial artery FMD (1.26 ± 3.06% vs -1.05 ± 2.84%); no effect on pulse wave velocity Surrogate measures only Abbreviations: BP , blood pressure; DBP , diastolic blood pressure; eGFR, estimated glomerular filtration rate; FMD, flow-mediated dilatation; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; NS, not significant; SBP , systolic blood pressure.
studies involving the general population rather than the CKD patient popula tion. Selecting patients for a uratelowering RCT requires striking the right balance between severity of chronic renal impairment and likelihood of reversal or stabilization of renal function. For example, patients with sufficiently advanced CKD (stages 3b or 4) will be at higher risk of reaching trial end points within the study time frame than those with earlier stages of CKD, which will increase the study power. Conversely, the likelihood of reversing the renal function trajectory of patients with advanced CKD might be reduced compared to those with earlier stages of CKD. Experience from pre vious trials with ACEIs and ARBs suggests that participants with milder CKD (stages 2 or 3a) are perhaps most likely to respond to the intervention, but will also experience lower event rates than those with CKD stages 3b or 4, thus needing a larger sample size and longer followup.
Other conditions that are likely to affect serum uric acid levels include: gender, dia betes mellitus, obesity, ethnicity, diuretic use, and use of ARBs (which have a uri cosuric effect). Even though known and unknown confounders are likely to be balanced between the intervention and control groups as a result of randomization, we propose that randomization should be stratified for gender, diabetes mellitus, BMI, and diuretic use. Major exclusion criteria for such a trial would be a clinically appropriate indication for uricacidlowering treatment (for example, uric acid calculi or a history of gout), concurrent immunosuppressive therapy (particularly azathioprine), previ ous kidney transplantation, and intoler ance or hypersensitivity to the therapeutic agent (for example, severe anemia and neutro penia, which are contraindications to allopurinol therapy).
Intervention
Allopurinol is a widely used and inexpensive uricacidlowering medication; however, it requires dose modification in the presence of reduced GFR. Moreover, its safety and tolerability in CKD are not well known, although rare adverse effects include aller gic skin rash and aplastic anemia. A pilot study could provide an opportunity to better define its safety and efficacy profile in this population.
Febuxostat, a selective xanthine oxidase inhibitor, has a better safety profile than allopurinol and has been shown to prevent progression of renal disease in 5/6 neph rectomy rats, 40 but there is less clinical experience with this agent and it is more expensive than allopurinol.
Appropriate bloodpressure control with a regimen that includes an ACEI or an ARB is the current standard of care in patients with CKD and proteinuria. Hence, any inter vention (allopurinol, or febuxostat versus placebo) should be given together with the best available antihypertensive therapy. with 5% of participants lost to followup, a crossover rate of 5% in each direction (from the treatment arm to the control arm, and vice versa)-310 patients per arm, or 620 patients in total, would have 90% power to show a 20% slower decline in eGFR after 2 years, using a conservative standard deviation for change in eGFR of 4 ml/min/1.73 m. 2 For the hard endpoint study in a study population that has a mean baseline eGFR of 55 ml/min/1.73 m 2 , 20% of participants will reach a composite end point (decrease in GFR by 50% or by ≥25 ml/min/1.73 m 2 , ESRD or death) over 3-5 years. Assuming a relative risk reduction of 20%, an accrual period of 2 years, a minimum followup of 3 years, 5% of patients lost to followup, a crossover rate of 5% in each direction, a power of 90%, and alpha error of 0.05, would require recruitment of 7,470 patients. For a study population with a mean base line eGFR of 40 ml/min/1.73 m 2 , assuming an event rate of 30% over 3-5 years, 4,900 patients would be required.
Sample size calculation

Operational and financial issues
Although a pilot trial could be conducted in a few sites in a single country, a trial exam ining major clinical outcomes would need to be implemented in many countries to be successful. A multinational, largescale trial involving thousands of patients would need close cooperation and coordination between clinical trialists interested in this field from around the world. Indeed, there is a need to form a global consortium of clinical trialists in nephrology to support and coordinate similar investigator initiated largescale trials. Securing adequate funds to maintain such large and invariably expensive trials would be a challenging task and would depend on a variety of sources, including government, professional societies, research foundations, and the pharmaceutical industry.
Conclusions
CKD is a global public health problem that is associated with an excess burden of cardiovascular disease, high mortality and poor quality of life. The development of interventions to prevent these complica tions has the potential to provide substan tial public health improvements and to be highly costeffective. A sufficient body of laboratory and clinical evidence now exists to justify an RCT of the use of uricacid lowering therapy in patients with CKD, as a potentially novel, costeffective strategy for improving renal and cardiovascular outcomes. We propose a multicenter, pilot RCT with surrogate end points to establish 'proofofconcept' and safety/tolerability profiles before proceeding to a largescale RCT with hard end points. Considering the large sample size required for these types of trials, an international collaboration of nephrologists is required and should be developed as a priority. 
